Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 6NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1Neuroblastoma 1

Interventions

Radiotherapy 58Temozolomide 37Vincristine 33Cyclophosphamide 31Etoposide 25Carboplatin 25Filgrastim 23Cisplatin 22Granulocyte Colony-Stimulating Factor 18Lomustine 14Doxorubicin 13Chemotherapy, Adjuvant 13Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Topotecan 11Radiation 11Isotretinoin 11Platinum 10sargramostim 9Specimen Handling 9Radiotherapy, Conformal 9Irinotecan 9Carmustine 91,2-diaminocyclohexaneplatinum II citrate 9etoposide phosphate 8Thiotepa 8Radiotherapy, Intensity-Modulated 8Radiosurgery 8Melphalan 8Immunohistochemistry 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × irinotecan sucrosofate × CNS × Clear all
NCT02013336 2022-03-31

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

South Plains Oncology Consortium

Phase 1 Unknown
30 enrolled
CNSSarcoma

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡